Project: Silk-fibroin interventional nano-trap for the treatment of glioblastoma.
| Acronym | GLIOSILK (Reference Number: EURONANOMED2019-075) |
| Duration | 01/01/2020 - 31/12/2022 |
| Project Topic | The two main limitations contributing to the failure of conventional therapy of certain solid tumours, among which glioblastoma (GB) is a typical example, are: i) treatment resistance and ii) sub-optimal delivery of active principles. A major de facto objective of GB treatment is the exclusive eradication of tumour cells infiltrated within healthy tissue margins. Our fully complementary “nanomedicine” consortium (2 academic or health research institute partners, 2 medicals, 1 industrial) allowed us to work on the revolutionary concept of trapping cancer cells in controlled area before elimination and to build a relevant GB cell trap. This innovation will no longer aims to convey the drug to its target but rather to bring the target to a controlled "biointeractive polymer deposit". In our project this GB trap will be capable to release a chemoattractant factor, initially exemplified by SDF-1a released from a biomimetic and brain biocompatible polymer, silk fibroin (SF). Our GLIOSILK project will include: 1) the production of SF nanodevices (nanoparticles, nanofibers, micro-nanoporous polymeric scaffold and hydrogels releasing SDF-1a); 2) the in vitro understanding of the nano-bio interface regarding the SDF-1a/CXCR4 axis in GB and stromal cells; 3) the study of the biocompatibility and localised toxicity of the micro-nano silk-fibroin based lead candidate; 4) a thorough preclinical evaluation in rat and in large swine GB model toward to possible clinical transfer. In fine, by use of well mastered cross-cutting methods, the capability of newly built biointeractive deposits to define a confined in situ gradient and to effectively trap GB cells before elimination (eg. by radiation therapy) while ameliorating the evolution of the disease will be determined. Overall, this multidisciplinary work's purpose is to make significant theoretical and technological breakthrough in overcoming treatment resistance in GB, and other solid tumours, toward clinical transfer. |
| Network | EuroNanoMed III |
| Call | Joint Transnational Call (2019) |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | INSERM - CRCINA | Coordinator | France |
| 2 | IDIS (Instituto de Investigación Sanitaria de Santiago de Compostela) - accredited Health Research Institute of the National Institute of Health Carlos III (ISCIII) - SPAIN | Partner | Spain |
| 3 | Centre Hospitalier Universitaire Grenoble Alpes (CHUGA) | Partner | France |
| 4 | Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia (AUSL-IRCCS) | Partner | Italy |
| 5 | NASASBIOTECH S.L. | Partner | Spain |